Marlana M. Orloff, MD

Marlana M. Orloff, MD, is an associate professor at Jefferson University and physician in the Department of Medical Oncology at Sidney Kimmel Cancer Center.

Articles

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

November 12th 2025

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Future Management of Uveal Melanoma

August 2nd 2021

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Uveal Melanoma: Patient Candidacy for Tebentafusp

August 2nd 2021

Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.

Tebentafusp for Uveal Melanoma: Cytokine Release Syndrome

August 2nd 2021

Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.

Tebentafusp for Uveal Melanoma: Adverse Events

August 2nd 2021

What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.

Uveal Melanoma: Sequencing Therapy

August 2nd 2021

Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.

Tebentafusp for Uveal Melanoma: Assessing Treatment Response

July 23rd 2021

Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.

Tebentafusp Efficacy Data in Uveal Melanoma

July 23rd 2021

Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.

Tebentafusp for Uveal Melanoma

July 23rd 2021

Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.

Uveal Melanoma: Current Treatment Approaches

July 23rd 2021

A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.